Kaken Pharmaceutical Co., Ltd
By therapeutic area
Not enough TA-specific data (need ≥3 deals per TA).
By stage at signing
| Phase | Premium | Deals |
|---|---|---|
| phase 3 | ×0.70 | 3 |
Strategy profile
Based on 5 disclosed transactions, Kaken Pharmaceutical Co., Ltd concentrates its licensing activity in RareDisease, WomensHealth, and Gastroenterology. Kaken Pharmaceutical Co., Ltd pays a 0.70x discount to market median. Their most common deal structure is License, with an average disclosed value of $100M. Most recent activity: 2025.
Pipeline coverage & gaps
Kaken Pharmaceutical Co., Ltd has disclosed activity in 0 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| LicensePrimary | 5 | $21M | $100M |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2025 | navenibart | Astria Therapeutics, Inc. | hereditary angioedema | phase_3 | $16M | $32M |
| 2025 | sebetralstat | KalVista Pharmaceuticals, Inc. | hereditary angioedema | phase_3 | $11M | $24M |
| 2023 | Tildacerfont | Spruce Biosciences | polycystic ovary syndrome (PCOS) | phase_2 | $15M | $80M |
| 2023 | Seladelpar | CymaBay Therapeutics | primary biliary cholangitis (PBC) | phase_3 | $34M | $162M |
| 2019 | lenabasum | Corbus Pharmaceuticals | systemic sclerosis, dermatomyositis | phase_3 | $27M | $200M |
How this is computed
For each Kaken Pharmaceutical Co., Ltd deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 4 disclosed deal premiums vs. peer medians. Raw premium 0.262, clamped to [0.7, 1.5].